Dyckhoff Gerhard, Warta Rolf, Herold-Mende Christel, Plinkert Peter K, Ramroth Heribert
Universitäts-Hals-Nasen-Ohrenklinik Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Deutschland.
Neurochirurgische Universitätsklinik Heidelberg, Heidelberg, Deutschland.
HNO. 2022 Aug;70(8):581-587. doi: 10.1007/s00106-022-01177-7. Epub 2022 May 16.
By today's standard, the optimal treatment of every individual tumor patient is discussed and determined in an interdisciplinary tumor board. According to the new S3 guidelines, larger volume T3 laryngeal cancers which are no longer safely resectable with larynx-sparing surgery are ideal candidates for a larynx preservation approach using primary chemoradiation (pCRT). So far, no clear criteria have been defined under what circumstances primary radiotherapy alone (pRT) might be acceptable in case chemotherapy (CT) is prohibited or in what cases, even in T3, upfront total laryngectomy with risk-adapted adjuvant treatment (TL±a[C]RT) should be recommended.
The literature was searched for parameters chosen as criteria for an inclusion in the surgical rather than the conservative arm in non-randomized LP studies or which proved to be significant prognostic markers after conservative treatment. Development of a counselling tool for therapeutic decision making.
Significant prognostic markers were tumor volume (< 3.5 ccm/< 6 ccm vs. 6-12 ccm vs. > 12 ccm), presence and kind of vocal cord fixation (none vs. Succo I/II vs. Succo III/IV), extent of cartilage infiltration (none vs. minimal vs. multiple/gross), nodal status (N0‑1 vs. N2-3), and laryngeal dysfunction (pretreatment necessity of feeding tube or tracheostomy).
For T3 laryngeal cancers, pRT could be acceptable when the tumor volume is < 3.5 ccm for glottic and < 6 ccm for supraglottic tumors and there are no further risk factors. pCRT can be regarded as the standard for LP for tumors between 6 ccm and 12 ccm, vocal cord fixation Succo pattern I/II, only minimal cartilage infiltration and a high nodal burden. For tumor > 12 ccm, vocal cord fixation Succo pattern III/IV, gross or multiple cartilage infiltration or clinically relevant laryngeal dysfunction, upfront TL±a[C]RT should be considered.
按照当今的标准,每位肿瘤患者的最佳治疗方案都在多学科肿瘤委员会中进行讨论和确定。根据新的S3指南,对于无法通过保留喉手术安全切除的较大体积T3喉癌,采用原发放化疗(pCRT)的喉保留方法是理想选择。到目前为止,尚未明确界定在化疗(CT)被禁止的情况下,何种情况下单独进行原发放疗(pRT)可能是可接受的,或者在哪些情况下,即使是T3期,也应推荐先行全喉切除术并进行风险适应性辅助治疗(TL±a[C]RT)。
检索文献,寻找在非随机喉保留研究中被选作纳入手术而非保守治疗组标准的参数,或在保守治疗后被证明是显著预后标志物的参数。开发一种用于治疗决策的咨询工具。
显著的预后标志物包括肿瘤体积(<3.5立方厘米/<6立方厘米 vs. 6 - 12立方厘米 vs. >12立方厘米)、声带固定的存在及类型(无 vs. 苏科I/II型 vs. 苏科III/IV型)、软骨浸润程度(无 vs. 轻微 vs. 多处/广泛)、淋巴结状态(N0 - 1 vs. N2 - 3)以及喉功能障碍(治疗前是否需要鼻饲管或气管切开术)。
对于T3喉癌,当声门型肿瘤体积<3.5立方厘米、声门上型肿瘤体积<6立方厘米且无其他危险因素时,pRT可能是可接受的。对于体积在6立方厘米至12立方厘米之间、声带固定为苏科I/II型、仅有轻微软骨浸润且淋巴结负荷高的肿瘤,pCRT可被视为喉保留的标准治疗方法。对于肿瘤>12立方厘米、声带固定为苏科III/IV型、广泛或多处软骨浸润或存在临床相关喉功能障碍的情况,应考虑先行TL±a[C]RT。